ArticleCell2014
Gut microbial metabolism drives transformation of MSH2-deficient colon epithelial cells.
Article in Cell, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 292 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
292 citing papers in PubMed, 2 syntheses or guidelines pooled it, 467 citations in OpenAlex.
- Unravelling novel microbial players in the breast tissue of TNBC patients: a meta-analytic perspective.NPJ biofilms and microbiomes · 2025Pooled it
- Systematic review on the role of the gut microbiota in tumors and their treatment.Frontiers in endocrinology · 2024Pooled it
- The cervicovaginal gut microbiota axis as a key determinant of systemic physiology.Gut microbes · 2026Review
- Faecalibacterium-derived spermidine mediates the amelioration of fatty liver hemorrhagic syndrome by inulin in laying hens.NPJ biofilms and microbiomes · 2026Article
- The gut microbiome and ageing trajectories: mechanisms and clinical implications.Nature reviews. Endocrinology · 2026Review
- Valeric acid from oral microbiome suppresses esophageal cancer growth by disrupting eEF1A1 -mediated translational output.Nature communications · 2026Article
- Discovery and characterization of Christensenella hongkongensis as a novel bacterium in the adenoma-carcinoma progression.Journal of translational medicine · 2026Article
- Modulating drug response through the gut microbiome: pathways to precision therapy.Archives of microbiology · 2026Review
- Gut microbiome-driven colorectal cancer via immune, metabolic, neural, and endocrine axes reprogramming.NPJ biofilms and microbiomes · 2026Review
- Association of oral microbiota and digestive system cancers revealed by bidirectional two sample Mendelian randomization.Discover oncology · 2026Article
- Gut microbiota-innate immune crosstalk in the initiation and progression of CRC: mechanisms and therapeutic potential.Frontiers in immunology · 2026Review
- Interkingdom microbiome physiology in colorectal cancer: barrier dysfunction, immune-metabolic signaling, and therapeutic resistance.Frontiers in physiology · 2026Review
- The gut microbiome in colorectal cancer: molecular paradigms and translational frontiers.Frontiers in bioengineering and biotechnology · 2026Review
- Taxonomy, carcinogenic mechanisms, and advanced molecular diagnosis of Fusobacterium nucleatum in colorectal cancer: from bench to clinical practice.Frontiers in immunology · 2026Review
- Translational approaches in microbiome research: from functional mechanisms to next-generation therapeutics.Frontiers in microbiology · 2026Review
- Microbiome dysbiosis and its modulation in cancer development, prevention and therapy.Frontiers in oncology · 2026Review
- From cooperation to collapse: the diet-microbiota-host gene triad in disease and aging.Frontiers in microbiomes · 2026Review
- Short-chain fatty acids in the tumor microenvironment: from molecular mechanisms to cancer therapy.Theranostics · 2026Review
- Decoding the power of the microbiome in human health.Frontiers in cellular and infection microbiology · 2026Review
- New insights in amino sugar metabolism by the gut microbiome.Gut microbes · 2025Review
232 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
22 authors at 6 institutions in 2 countries.
Funding
Abstract
The etiology of colorectal cancer (CRC) has been linked to deficiencies in mismatch repair and adenomatous polyposis coli (APC) proteins, diet, inflammatory processes, and gut microbiota. However, the mechanism through which the microbiota synergizes with these etiologic factors to promote CRC is not clear. We report that altering the microbiota composition reduces CRC in APC(Min/+)MSH2(-/-) mice, and that a diet reduced in carbohydrates phenocopies this effect. Gut microbes did not induce CRC in these mice through an inflammatory response or the production of DNA mutagens but rather by providing carbohydrate-derived metabolites such as butyrate that fuel hyperproliferation of MSH2(-/-) colon epithelial cells. Further, we provide evidence that the mismatch repair pathway has a role in regulating β-catenin activity and modulating the differentiation of transit-amplifying cells in the colon. These data thereby provide an explanation for the interaction between microbiota, diet, and mismatch repair deficiency in CRC induction. PAPERCLIP:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.